The Business Research Company’s Multiple Sclerosis Drugs Global Market Report 2021: COVID-19 Impact and Recovery To 2030
LONDON, GREATER LONDON, UK, July 15, 2021 /EINPresswire.com/ — According to the new market research report ‘Multiple Sclerosis Drugs Global Market Report 2021: COVID-19 Growth And Change To 2030’ published by The Business Research Company, the global multiple sclerosis drugs market is expected to grow from $21.27 billion in 2020 to $22.04 billion in 2021 at a compound annual growth rate (CAGR) of 3.6%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The multiple sclerosis drugs market is expected to reach $25.95 billion in 2025 at a CAGR of 4%. The growth of multiple sclerosis drugs market is aided by the support from government as well as non-government organization.
Request For A Sample For The Global Multiple Sclerosis Drugs Market Report:
The multiple sclerosis drugs market consists of sale of multiple sclerosis drugs and related services. Multiple sclerosis (MS) is an autoimmune disease where the immune system attacks the protective fat layer called myelin, around the nerve fibers and causes problems with muscle control, vision and other body functions. It is a disease that affects brain, spinal cord and the optic nerves resulting in loss of balance, coordination and compromised vision. The disease can result in long term disability.
Trends In The Global Multiple Sclerosis Drugs Market
The companies are rapidly intensifying their efforts to focus on new product launches to cater to the rising demands for MS drugs. The multiple sclerosis requires a lifelong treatment, which increases the overall cost of treating a patient. In order to provide better and effective treatment companies in the multiple sclerosis market are developing drugs specific to the treatment of multiple sclerosis. Following the trend, in 2019, FDA approved Novartis’ Mayzent (siponimod) and EMD Serono’s Mavenclad (cladribrine) for the treatment of relapsing remitting multiple sclerosis (RRMS), and active secondary progressive multiple sclerosis (SPMS). Both the drugs were launched as an easy-to-consume oral drug.
Global Multiple Sclerosis Drugs Market Segments:
The global multiple sclerosis drugs market is further segmented based on drug class, distribution channel, route of administration and geography.
By Drug Class: Immunomodulators, Immunosuppressants, Interferons, Others
By Distribution Channels: Hospital Pharmacy, Retail Pharmacy, Online Stores
By Route Of Administration: Oral Drugs, Parenteral Drugs
By Geography: The global multiple sclerosis drugs market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa.
Read More On The Report For The Global Multiple Sclerosis Drugs Market At:
Multiple Sclerosis Drugs Global Market Report 2021 is one of a series of new reports from The Business Research Company that provides multiple sclerosis drugs global market overviews, analyzes and forecasts market size and growth for the multiple sclerosis drugs global market, multiple sclerosis drugs global market share, multiple sclerosis drugs global market players, multiple sclerosis drugs market segments and geographies, multiple sclerosis drugs market’s leading competitors’ revenues, profiles and market shares. The multiple sclerosis drugs market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.
Read Multiple Sclerosis Drugs Global Market Report 2021 from The Business Research Company for information on the following:
Data Segmentations: Market Size, Global, By Region And By Country; Historic And Forecast Size, And Growth Rates For The World, 7 Regions And 12 Countries
Multiple Sclerosis Drugs Market Organizations Covered: Biogen, Novartis, Roche, Bayer HealthCare, Pfizer Inc., Merck & Co. Inc.
Regions: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
Interested to know more about The Business Research Company?
The Business Research Company has published over 1000 industry reports, covering over 2500 market segments and 60 geographies. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. The reports are updated with a detailed analysis of the impact of COVID-19 on various markets.
Here is a list of reports from The Business Research Company similar to the Multiple Sclerosis Drugs Global Market Report 2021:
Autoimmune Disease Diagnosis Global Market Report 2021: COVID-19 Growth And Change To 2030
Drugs For Immunotherapy Global Market Report 2021: COVID-19 Growth And Change To 2030
Immunosuppressants Global Market Report 2021: COVID-19 Growth And Change To 2030
Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293